Change is afoot at the helm of international pharma company Sanofi, as it announces the departure of a key leadership figure from its research and development team.
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
A federal appeals court in the US has ruled in favour of three pharma companies in a dispute over the supply of discounted medicines to contract pharmacies with the Health
Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel
Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an
The clock has started ticking on the FDA's review of Sanofi and AstraZeneca's one-shot antibody to protect newborns and infants from respiratory syncytial virus (RSV), with a decision due i